Wouldn't another deal with hti be fairly far off? Why would companies not wait to see if the Roche deal pans out?Also, why wouldn't companies use the bovine version of the enzyme its cheaper...and would patients really care?
wow....no one to debate with :-Panyway...looking good...RJ's additional investment at 9.17 /share is very encouraging.
Well...I guess the latest baxter release indirectly answered my bovine question. Essentially they could never get a stable consistent supply of the bovine version to use broadly. Now that they are able to make the human version in quantity, its use will become more wide spread.-pokerden
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |